HilleVax $115 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the joint book-running managers in connection with the $115 million SEC-registered follow-on offering of 9,200,000 shares of common stock by HilleVax (which includes the exercise in full by the underwriters of their option to purchase up to 1,200,000 additional shares). The common stock is listed on the Nasdaq Global Select Market under the symbol “HLVX.”
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Paula Gergen and Jacquiley Wong. The intellectual property team included partner David R. Bauer, and associate Brette L. Trost. The tax team included partner Corey M. Goodman and associate Justin Corvino. Members of the Davis Polk team are based in the Northern California and New York offices.